Chelsie Derman

Maternal SSRI use was linked to a higher risk of constipation in infants, while untreated maternal depression was tied to colic. Margolis discussed these findings at NASPGHAN.

Silberg urges wider physician education on celiac screening, stressing that guidelines must reach primary care to address disparities and misconceptions.

A study presented at NASPGHAN 2024 found only 10% of eligible kids were screened for celiac disease. Debra Silberg, MD, PhD, urges unbiased, consistent screening.

Emraclidine fails to significantly reduce schizophrenia symptoms in phase 2 EMPOWER trials, with no statistical difference from placebo on PANSS score.

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

At NASPGHAN 2024, Sadaka shared results of a study demonstrating the factors associated with a longer hospital stay for children with gastroparesis.

HCPLive spoke to Sadaka at NASPHAN 2024 about the increase in hospital admissions among children with gastroparesis after the COVID-19 pandemic.

At NASPGHAN 2024, HCPLive spoke to Shameem about his study on inpatient outcomes of pediatric patients with IBD and GAD vs patients without GAD.

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

Phase 3 data shows lumateperone 42 mg significantly delayed relapse in patients with schizophrenia vs placebo, with 63% reduced relapse risk and good tolerance.

Teva presents 2 findings at the 2024 psychiatry conference: TEV’749’s effects on social function and quality of life in adults with schizophrenia and risperidone adherence patterns.

Chronic hepatitis B patients with HBsAg <100 IU/mL and HBcrAg <3 log U/mL at nucleot(s)ide analog therapy had lower relapse risk.

Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.

Clinical images help pathologists improve diagnostic confidence and agreement, leading to more accurate diagnoses of melanocytic skin lesions.

More patients with atopic dermatitis on stapokibart than on placebo achieved ≥ 75% improvement in Eczema Area and Severity Index over 52 weeks.

Neither clinician peer comparison nor patient informational mail reduced benzodiazepine use among older adults in anesthesia care, a new study finds.

In a recent phase 2a trial, SPN-820, a novel intracellular moderator of mTORC1, decreased suicidal ideation by 80%.

This Month in Review captures top FDA news, phase 2b data, and early research in the psychiatry field.

EMERGENT-4 and EMERGENT-5, phase 3, 52-week trials, showed xanomeline trospium chloride significantly improved schizophrenia symptoms across 52 weeks.

T-VASI and F-VASI are validated, responsive tools for assessing vitiligo severity and re-pigmentation, with meaningful change thresholds established.

Sexual trauma and genetic risk independently and together raise mental illness risk, a new study found.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Many with moderate-to-severe atopic dermatitis do not reach treatment targets in 12 months, underscoring a need for proactive management strategies.

A study revealed using language models as diagnostic aids did not significantly enhance clinical reasoning or accuracy among physicians over conventional resources alone.

Psychology referrals for children with food allergies surged 11-fold in the last decade, but many still face limited access to therapy services due to geographic barriers.

A new study found that individuals with healthier cardiovascular systems are more likely to develop migraines, linking incident migraine to lower cardiovascular risk.

Alto Neuroscience's ALTO-100 failed to beat placebo in a phase 2b trial for depression, leading to a 60% stock drop.

In the complete response letter, the FDA classified deficiencies in the Abbreviated New Drug Application for ketamine as MINOR.

A study found people with schizophrenia have a 4-fold higher risk of sudden cardiac death compared to the general population, underscoring the need for cardiometabolic care.